ROS1 fusions in Chinese patients with non-small-cell lung cancer
| Autor: | W. Cai, L. Zheng, K. Fei, Caicun Zhou, C. Su, G. Schmid-Bindert, X. Li, L. Fan, Christian Manegold |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Pathology Lung Neoplasms Oncogene Proteins Fusion Adenosquamous carcinoma Kaplan-Meier Estimate Adenocarcinoma Carcinoma Adenosquamous Gefitinib Asian People Carcinoma Non-Small-Cell Lung Proto-Oncogene Proteins Internal medicine medicine ROS1 Humans Anaplastic lymphoma kinase Stage (cooking) Lung cancer Pathological Genetic Association Studies Aged Aged 80 and over Base Sequence Reverse Transcriptase Polymerase Chain Reaction business.industry Sequence Analysis DNA Hematology Middle Aged Protein-Tyrosine Kinases Prognosis medicine.disease Multivariate Analysis Female business medicine.drug |
| Zdroj: | Annals of Oncology. 24:1822-1827 |
| ISSN: | 0923-7534 |
| Popis: | Received 27 November 2012; revised 25 January 2013; accepted 28 January 2013 Background: To determine the prevalence and clinicopathological features of ROS1 fusions in Chinese patients with non-small-cell lung cancer (NSCLC). Methods: Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 392 patients with NSCLC were screened for ROS1 fusions by multiplex RT–PCR and all ROS1 fusions were validated by direct sequencing. The relationship between ROS1 fusions and clinicopathological features and the prognostic effect of the ROS1 fusion status on survival were analyzed. Results: In this study, 8 of 392 (2.0%) evaluable samples were found to harbor ROS1 fusions. Of the ROS1-positive patients, seven presented with adenocarcinoma, and one with adenosquamous carcinoma. The ratio of female to male and never smoker to smokers in a ROS1 fusion-positive group was 5:3. There was no statistically significant difference in age, sex, smoking history, histological type and pathological stage between ROS1 fusion-positive and ROS1 fusionnegative patients. ROS1 fusion-negative patients had a significantly longer survival when compared with ROS1 fusionpositive patients (P= 0.041). Lower pathological stage, younger age and ROS1 fusion-negative status were significantly associated with better prognosis on multivariate analysis. Conclusions: ROS1 fusions occurred in ∼2.0% of Chinese patients with NSCLC and had no specific clinicopathological feature. ROS1 fusion-negative patients may have a better survival than ROS1 fusion-positive |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|